Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Average Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $28.83.

Several research firms recently commented on IMNM. Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th.

Insider Activity at Immunome

In other Immunome news, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was acquired at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert Lechleider bought 15,805 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares in the company, valued at $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 102,862 shares of company stock worth $978,045 in the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in shares of Immunome in the second quarter valued at approximately $81,000. Arizona State Retirement System lifted its stake in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. Intech Investment Management LLC purchased a new position in Immunome during the third quarter worth about $219,000. Finally, Profund Advisors LLC acquired a new stake in Immunome in the second quarter valued at about $262,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Up 1.3 %

Shares of IMNM stock opened at $9.99 on Wednesday. The firm has a market cap of $623.58 million, a price-to-earnings ratio of -1.23 and a beta of 1.90. Immunome has a 52-week low of $8.97 and a 52-week high of $30.96. The company’s 50 day moving average is $11.47 and its 200 day moving average is $12.92.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.